A detailed history of Bank Of America Corp transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 98,032 shares of PHAT stock, worth $933,264. This represents 0.0% of its overall portfolio holdings.

Number of Shares
98,032
Previous 105,855 7.39%
Holding current value
$933,264
Previous $1.12 Million 10.23%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$8.97 - $12.05 $70,172 - $94,267
-7,823 Reduced 7.39%
98,032 $1.01 Million
Q1 2024

May 15, 2024

BUY
$6.21 - $11.05 $149,425 - $265,885
24,062 Added 29.42%
105,855 $1.12 Million
Q4 2023

Feb 14, 2024

BUY
$6.99 - $10.71 $179,719 - $275,364
25,711 Added 45.85%
81,793 $746,000
Q2 2023

Aug 14, 2023

SELL
$7.28 - $14.32 $1.44 Million - $2.83 Million
-197,403 Reduced 77.88%
56,082 $803,000
Q1 2023

May 12, 2023

BUY
$6.19 - $12.36 $1.16 Million - $2.32 Million
188,023 Added 287.22%
253,485 $1.81 Million
Q4 2022

Feb 10, 2023

SELL
$9.18 - $11.53 $48,525 - $60,947
-5,286 Reduced 7.47%
65,462 $734,000
Q3 2022

Nov 14, 2022

SELL
$6.46 - $12.11 $134,342 - $251,839
-20,796 Reduced 22.72%
70,748 $784,000
Q2 2022

Aug 12, 2022

BUY
$6.2 - $15.5 $154,280 - $385,702
24,884 Added 37.33%
91,544 $772,000
Q1 2022

May 16, 2022

SELL
$11.55 - $20.06 $89,293 - $155,083
-7,731 Reduced 10.39%
66,660 $908,000
Q4 2021

Feb 08, 2022

BUY
$17.83 - $33.15 $175,750 - $326,759
9,857 Added 15.27%
74,391 $1.46 Million
Q3 2021

Nov 15, 2021

BUY
$30.69 - $36.83 $30,383 - $36,461
990 Added 1.56%
64,534 $2.07 Million
Q2 2021

Sep 13, 2021

BUY
$32.66 - $39.87 $2.08 Million - $2.53 Million
63,544 New
63,544 $2.15 Million

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $373M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.